Supplementary methods

Cell culture

The HCC cell lines (HUH-7 and Hep3B) were obtained from the National Collection of Authenticated Cell Cultures (Shanghai, China). Briefly, HUH-7 and Hep3B cells were cultured in DMEM and MEM containing 10% FBS and 1% antibiotic-antimycotic, respectively. Cells were incubated in a 37 °C incubator with 5% CO₂. Cells were authenticated before the experiment.

Transient transfection

HCC cells were planted into a 6-well plate at a density of 75% confluence. Then, ATG5-, ATG3-, YTHDF1-, and BHMT-specific small interfering RNA (siRNA) and negative control (NC) transfection were mixed with Opti-MEM and lipofectamine 3000, respectively. After being incubated for 20 min, the mixture was subjected to HCC cells and cultured for 8 h. Subsequently, the mixture was removed and fresh medium was added for further cultivation for 48 h. Finally, cells were harvested for subsequent experiments. The sequence of the siRNAs and NC was listed in Table S3.

Construction of stable transfected cell line

To obtain a stable transfected cell line, the recombined lentiviruses harboring ATG5 and ATG3 short hairpin RNA (shRNA) as well as scrambled lentiviral constructs (shNC) were designed and constructed by GenePharm company (Soochow, China). Briefly, after HCC cells in 12-well plate reached a confluence of 35%, lentivirus was added into each well and cultured for 8 h. Then, 1 mL of fresh medium was added and further incubated for 48 h. Afterwards, the medium was removed and fresh medium containing $2.5 \mu g/mL$ of puromycin was added for 14 days to select stable cell lines. The sequences of shRNA (ATG5 and ATG3) and shNC (NC) were listed in Table S4.

CCK-8 assay

CCK-8 assay was conducted to detect the effect of betaine on the viability of HCC cells. Briefly, 5000 HCC cells were planted into a 96-well plate and subjected to different concentrations of betaine for 24 h. Then, the medium was removed and 90 μ L of fresh medium along with 10 μ L of CCK-8 reagent were added into each well. After being incubated at 37 °C for 2 h, the absorbance of each well was detected by a microplate reader at 450 nm. The IC50 values of betaine against HCC cells were calculated according to the concentration and absorbance.

Colony formation assay

Colony formation assay was performed to detect the cell clonogenic ability. Briefly, HCC spheres with different treatments were dissociated into a single cell using accutase, and 400 cells suspended in 2 mL of medium were planted into a 12-well plate and incubated for 10 days. Then, the medium was removed, and the cells were washed with PBS and fixed with 4% paraformaldehyde. Subsequently, the cells were stained with crystal violet for 30 min and washed. After drying, images were captured and the colonies were counted.

Transwell migration and invasion assays

Transwell migration and invasion assays were conducted to measure cell motility. First, HCC spheres with different treatments were dissociated into a single cell by accutase. In the transwell migration assay, 5000 cells suspended in 100 μ L of fresh medium were added into the upper chamber, while 500 μ L of fresh medium was added into the lower chamber. After being cultured for 48 h, cells in the upper chamber were gently removed. Then, cells in the lower chamber were fixed with 4% paraformaldehyde for15 min and stained with crystal violet for 20 min. Finally, images were captured using a light microscope, and the migrated cells were calculated by ImageJ software.

For the transwell invasion assay, 50 μ L of Matrigel (Corning, New York, USA) was pre-coated in the upper chamber for 2 h in the incubator. Then, 10,000 cells diluted in 100 μ L of fresh medium were planted into the upper chamber. The remaining procedures followed the migration assay.

Western blots

Total proteins in HCC cells and tissues were extracted using RIPA lysis buffer containing 1% PMSF and 1% protease inhibitor. After quantification and denaturation, about 15-30 µg of proteins were added into sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) for separation. Then, the proteins were transferred to a polyvinylidene fluoride (PVDF) membrane for 2 h. Afterwards, the membrane was blocked with 5% skim milk at room temperature for 1 h and washed with TBST for 15 min. After incubation with primary antibodies overnight at 4 °C, the membrane was washed and incubated with secondary antibody at room temperature for 2 h. Subsequently, the membrane was washed and detected by enhanced chemiluminescence. The band density of proteins was measured by ImageJ software. Details of antibodies were listed in Table S5.

RNA isolation, cDNA synthesis, and quantitative polymerase chain reaction

Total RNA in HCC cells and tissues was isolated using a commercial TransZOL kit. After quantification, about 100 ng of RNA was subjected to cDNA synthesis using TransScript® II One-Step gDNA Removal and cDNA Synthesis SuperMix kit (TransGen Biotech, Beijing, China) according to the guideline of manufacturer. Then, relative gene expression was determined via quantitative polymerase chain reaction (qPCR) method using a TransStart Top Green qPCR SuperMix Kit (TransGen Biotech) following the manufacturers' instructions. The expression of genes was normalized to 18S rRNA and calculated using the $2^{-\Delta\Delta CT}$ method. The primer sequences were listed in Table S6.

Enzyme-linked immunosorbent assay

The level of SAM in PDX tumor tissues and HCC cells was detected using a commercial enzyme-linked immunosorbent (ELISA) kit (JonIn, Shanghai, China) according to the manufacturer's protocol.

Bioinformatic analysis

The correlation of ATG3 and YTHDF1 in HCC tissues was analyzed using the online GEPIA 2 software according to its instruction.

Hematoxylin & Eosin staining

After the tissues were fixed with 4% paraformaldehyde, embedded with paraffin, and sectioned, about 4 µm thick of tissues were subjected to Hematoxylin & Eosin (H&E) staining. The images of H&E-stained tissues were captured using a light microscope. For tail vein-lung metastasis assay, the metastatic nodules were counted under the microscope.

Immunohistochemistry assay

For the immunohistochemistry (IHC) assay, 4 μ m thick of tissues were subjected to xylene for deparaffinization and graded ethanol for rehydration. Then, tissues were boiled in EDTA (pH = 8.0) for 30 min for antigen retrieval. Afterward, 3% H₂O₂ was used to quench the endogenous peroxidase. Subsequently, the tissues were blocked with 1% BSA for 20 min at room temperature. After being washed with PBS for 3 times, the tissues were incubated with primary antibody overnight at 4 °C in a humid chamber. Then, tissues were washed with PBS and incubated with second antibodies at room temperature for 20 min in a humid chamber. After being washed, the tissues were stained with DAB reagent and hematoxylin. Finally, the tissues were sealed with neutral balsam and images were captured with a light microscope.

Immunofluorescence assay

For immunofluorescence (IF) assay, the procedures from deparaffinization to primary antibodies incubation followed the IHC assay. After being washed with PBS, the tissues were incubated with different species-derived secondary antibodies at 4 °C for 2 h at room temperature. Then, the tissues were incubated with DAPI (Beyotime) for 5 min and sealed with anti-fluorescence quenching buffer. Finally, images were captured using a fluorescence microscope.

Ge	sequence
ne	
	ATGTCGGCCACCAGCGTGGACACCCAGAGAACAAAAGGACAAGATAATAAAG
	TACAAAATGGTTCGTTACATCAGAAGGATACAGTTCATGACAATGACTTTGAG
	CCCTACCTTACTGGACAGTCAAATCAGAGTAACAGTTACCCCTCAATGAGCGA
	CCCCTACCTGTCCAGCTATTACCCGCCGTCCATTGGATTTCCTTACTCCCTCAAT
	GAGGCTCCGTGGTCTACTGCAGGGGGACCCTCCGATTCCATACCTCACCACCTA
	CGGACAGCTCAGTAACGGAGACCATCATTTTATGCACGATGCTGTTTTTGGGC
h-	AGCCTGGGGGGCCTGGGGGAACAACATCTATCAGCACAGGTTCAATTTTTTCCCT
YT	GAAAACCCTGCGTTCTCAGCATGGGGGGACAAGTGGGTCTCAAGGTCAGCAGA
Н	CCCAGAGCTCCGCGTATGGGAGCAGCTACACCTACCCCCCGAGCTCCCTGGGT
DF	GGCACGGTGGTTGATGGGCAGCCAGGCTTTCACAGCGACACCCTCAGCAAGG
1-	CCCCCGGGATGAACAGCCTGGAGCAGGGCATGGTTGGCCTGAAGATTGGGGA
wt	CGTCAGCTCCTCCGCCGTCAAGACGGTGGGCTCTGTCGTCAGCAGCGTGGCA
	CTGACTGGTGTCCTTTCTGGCAACGGTGGGACAAATGTGAACATGCCAGTTTC
	AAAGCCGACCTCGTGGGCTGCCATTGCCAGCAAGCCTGCAAAACCACAGCCT
	AAAATGAAAAAAAAGAGCGGGCCTGTCATGGGGGGGGGG
	CCATAAAGCATAACATGGACATTGGCACCTGGGATAACAAGGGGCCTGTGCCG
	AAGGCCCCAGTCCCCCAGCAGGCACCCTCTCCACAGGCTGCCCCACAGCCCC
	AGCAGGTGGCTCAGCCTCTCCCAGCACAGCCCCCAGCTTTGGCTCAACCGCA
	GTATCAGAGCCCTCAGCAGCCACCCCAGACCCGCTGGGTTGCCCCACGCAAC
	AGAAACGCGGCGTTTGGGCAGAGCGGAGGGGGCTGGCAGCGATAGCAACTCTC
	CTGGAAACGTCCAGCCTAATTCTGCCCCCAGCGTCGAATCCCACCCCGTCCTT
	GAAAAACTGAAGGCTGCTCACAGCTACAACCCGAAAGAGTTTGAGTGGAATC
	TGAAAAGCGGGCGTGTGTTCATCATC <mark>AAGAGCTAC</mark> TCTGAGGACGACATCCAC
	CGCTCCATTAAGTACTCCATCTGGTGTAGCACAGAGCACGGCAACAAGCGCCT
	GGACAGCGCCTTCCGCTGCATGAGCAGCAAGGGGGCCCGTCTACCTGCTCTTCA
	GCGTCAATGGGAGTGGGCATTTTTGTGGGGGTGGCCGAGATGAAGTCCCCCGTG
	GACTACGGCACCAGTGCCGGGGTCTGGTCTCAGGACAAGTGGAAGGGGAAGT
	TTGATGTCCAGTGGATTTTTGTTAAGGATGTACCCAATAACCAGCTCCGGCACA
	TCAGGCTGGAGAATAACGACAACAAACCGGTCACAAACTCCCGGGACACCCA
	GGAGGTGCCCTTAGAAAAAGCCAAGCAAGTGCTGAAAATTATCAGTTCCTACA
	AGCACACAACCTCCATCTTCGACGACTTTGCTCACTACGAGAAGCGCCAGGA
	GGAGGAGGAGGTGGTGCGCAAGGAACGGCAGAGTCGAAACAAAC
	ATGTCGGCCACCAGCGTGGACACCCAGAGAACAAAAGGACAAGATAATAAAG
	TACAAAATGGTTCGTTACATCAGAAGGATACAGTTCATGACAATGACTTTGAG
	CCCTACCTTACTGGACAGTCAAATCAGAGTAACAGTTACCCCTCAATGAGCGA
	CCCCTACCTGTCCAGCTATTACCCGCCGTCCATTGGATTTCCTTACTCCCTCAAT
h-	GAGGCTCCGTGGTCTACTGCAGGGGGACCCTCCGATTCCATACCTCACCACCTA
ΥT	CGGACAGCTCAGTAACGGAGACCATCATTTTATGCACGATGCTGTTTTTGGGC
Η	AGCCTGGGGGCCTGGGGAACAACATCTATCAGCACAGGTTCAATTTTTTCCCT

Table S1. YTHDF1 wild type and mutant sequence

GAAAACCCTGCGTTCTCAGCATGGGGGACAAGTGGGTCTCAAGGTCAGCAGA DF 1-CCCAGAGCTCCGCGTATGGGAGCAGCTACACCTACCCCCCGAGCTCCCTGGGT **K3** GGCACGGTGGTTGATGGGCAGCCAGGCTTTCACAGCGACACCCTCAGCAAGG 95 CCCCCGGGATGAACAGCCTGGAGCAGGGCATGGTTGGCCTGAAGATTGGGGA **A**/ CGTCAGCTCCTCCGCCGTCAAGACGGTGGGCTCTGTCGTCAGCAGCGTGGCA Y3 CTGACTGGTGTCCTTTCTGGCAACGGTGGGACAAATGTGAACATGCCAGTTTC 97 AAAGCCGACCTCGTGGGCTGCCATTGCCAGCAAGCCTGCAAAACCACAGCCT AAAATGAAAACAAAGAGCGGGCCTGTCATGGGGGGGTGGGCTGCCCCCTCCAC A CCATAAAGCATAACATGGACATTGGCACCTGGGATAACAAGGGGCCTGTGCCG AAGGCCCCAGTCCCCCAGCAGGCACCCTCTCCACAGGCTGCCCCACAGCCCC AGCAGGTGGCTCAGCCTCTCCCAGCACAGCCCCCAGCTTTGGCTCAACCGCA GTATCAGAGCCCTCAGCAGCCACCCCAGACCCGCTGGGTTGCCCCACGCAAC AGAAACGCGGCGTTTGGGCAGAGCGGAGGGGGCTGGCAGCGATAGCAACTCTC CTGGAAACGTCCAGCCTAATTCTGCCCCCAGCGTCGAATCCCACCCCGTCCTT GAAAAACTGAAGGCTGCTCACAGCTACAACCCGAAAGAGTTTGAGTGGAATC TGAAAAGCGGGCGTGTGTTCATCATC GCTCCATTAAGTACTCCATCTGGTGTAGCACAGAGCACGGCAACAAGCGCCTG GACAGCGCCTTCCGCTGCATGAGCAGCAAGGGGCCCGTCTACCTGCTCTTCAG CGTCAATGGGAGTGGGCATTTTTGTGGGGGTGGCCGAGATGAAGTCCCCCGTGG ACTACGGCACCAGTGCCGGGGGTCTGGTCTCAGGACAAGTGGAAGGGGAAGTT TGATGTCCAGTGGATTTTTGTTAAGGATGTACCCAATAACCAGCTCCGGCACAT CAGGCTGGAGAATAACGACAACAAACCGGTCACAAACTCCCGGGACACCCAG GAGGTGCCCTTAGAAAAAGCCAAGCAAGTGCTGAAAATTATCAGTTCCTACAA GCACACAACCTCCATCTTCGACGACTTTGCTCACTACGAGAAGCGCCAGGAG

Number	Age	Gender	Betaine level (µmol/L)
NO0684	29	1	21
NO0239	53	1	33
NO0841	37	1	35
NO0658	44	1	39
NO0234	64	1	40
NO0944	65	1	41
NO0029	34	1	42
NO0952	66	0	43
NO0230	38	0	44
NO0969	60	1	46
NO0010	69	1	46
NO0665	58	1	47
NO0020	76	1	47
NO0023	50	1	49
NO0867	67	1	49
NO0009	56	1	49
NO0835	71	0	50
NO0288	36	1	50
NO0645	55	1	51
NO0748	63	1	53
NO0238	56	1	53
NO0006	46	1	54
NO0806	59	0	55
NO0879	47	1	55
NO0046	41	1	55
NO0882	54	1	56
NO0685	35	1	58
NO0005	55	1	59
NO0307	35	1	59
NO0818	45	1	60
NO0007	62	1	61
NO0917	61	1	61
NO0249	58	1	62
NO0951	61	1	63
NO0279	40	1	63
NO0842	42	1	64
NO0244	73	0	64
NO0938	50	1	65
NO0693	57	0	67
NO0843	49	1	68
NO0826	63	1	69
NO0866	41	1	69

Table S2. Serum betaine concentrations of HCC patients

N	JO0731	55	1	69
Ν	100729	49	1	70
Ν	JO0024	47	1	70
N	JO0981	58	1	74
Ν	100833	41	1	76
Ν	JO0038	65	0	76
Ν	100002	80	1	77
Ν	JO0014	71	1	79
Ν	100669	40	1	80
Ν	JO0751	52	1	80
Ν	JO0719	64	1	80
Ν	JO0034	50	1	81
Ν	100809	36	1	82
N	JO0688	20	0	82
Ν	100752	65	1	82
N	JO0812	35	1	83
Ν	JO0710	49	1	84
N	100229	47	1	84
Ν	100942	54	0	87
N	100780	53	1	91
Ν	100039	44	1	91
N	JO0016	46	1	92
N	100289	33	1	93
Ν	100650	51	1	100
Ν	JO0001	58	1	104
N	100690	37	1	108
Ν	100698	59	1	109
Ν	JO0877	64	1	131

siRNA	Sequence
Scrambled	5'-UUCUCCGAACGUGUCACGUTT-3'
siATG5 #1	5'- GGUUUGGACGAAUUCCAACUUGUUU -3'
siATG5 #2	5'- GAUCACAAGCAACUCUGGAUGGGAU-3'
siATG3 #1	5'-CUCAAGGAAUCAAAGUUUATT-3'
siATG3 #2	5'- GGGUAGAUACAUAUCACAATT -3'
siBHMT #1	5'- GCAGCUGAAAGAGCUCUUUTT-3'
siBHMT #2	5'- GCUGUGGAUUUGAGCCCUATT-3'
siYTHDF1 #1	5'- GGAAACGUCCAGCCUAAUUTT-3'
siYTHDF1 #2	5'- CCUACGGACAGCUCAGUAATT-3'

Table S3. Small interference RNA sequences

shRNA	Sequence
LV16NC	5'-TTCTCCGAACGTGTCACGT-3'
shATG5 #1	5'- CAGCTCTTCCTTGGAACATCA -3'
shATG5 #2	5'- ATGAGACAAGAAGACATTAGT -3'
shATG3 #1	5'-CATATCACAACACAGGTATTA-3'
shATG3 #2	5'-GTACATCACTTACGACAAATA-3'

Table S4. shATG5 and shATG3 sequences

Antibody	Company	Catalog	Concentration
E-cadherin	ABclonal	A20798	1:1000
N-cadherin	ABclonal	A19083	1:2000
Vimentin	ABclonal	A19607	1:10000
MMP2	ABclonal	A6247	1:500
CD133	Cell Signaling technology	64326	1:1000 for WB, 1:500 for IF
CD44	ABclonal	A19020	1:1000
ЕрСАМ	ABclonal	A19301	1:10000
SOX2	Cell Signaling technology	23064	1:1000
Nanog	Cell Signaling technology	4903	1:1000 for WB, 1:200 for IF
Ki-67	ABclonal	A26200	1:500
PCNA	ABclonal	A12427	1:1000
LC3B	Cell Signaling technology	2775	1:1000
LC3B	Cell Signaling technology	83506	1:400 for IF
ATG3	Cell Signaling technology	3415	1:1000
ATG5	ABclonal	A19677	1:1000
ВНМТ	ABclonal	A5134	1:1000
YTHDF1	Cell Signaling technology	57530	1:1000
m ⁶ A	ABclonal	A19841	1:1000
АСТВ	ABclonal	AC038	1:10000
TRITC-conjugated	Jackson ImmunoResearch	115-025-062	1:100
AffiniPure Goat Anti-Mouse			
IgG (H+L)			
FITC AffiniPure™ Goat	Jackson ImmunoResearch	111-095-003	1:100
Anti-Rabbit IgG (H+L)			
HRP Goat Anti-Rabbit IgG	ABclonal	AS014	1:5000

Table S5. Details of antibodies

Gene	Primers (5'→3')
CD133	Fwd AGTCGGAAACTGGCAGATAGC
	Rev GGTAGTGTTGTACTGGGCCAAT
CD44	Fwd CTGCCGCTTTGCAGGTGTA
	Rev CATTGTGGGCAAGGTGCTATT
SOX2	Fwd GCCGAGTGGAAACTTTTGTCG
	Rev GGCAGCGTGTACTTATCCTTCT
Nanog	Fwd AATACCTCAGCCTCCAGCAGATG
	Rev TGCGTCACACCATTGCTATTCTTC
ATG10	Fwd AGACCATCAAAGGACTGTTCTGA
	Rev GGGTAGATGCTCCTAGATGTGAC
ATG12	Fwd TAGAGCGAACACGAACCATCC
	Rev CACTGCCAAAACACTCATAGAGA
ATG13	Fwd AGACAGTTCGTGTTGGGACAG
	Rev AGACAGTTCGTGTTGGGACAG
ATG14	Fwd GCAAATCTTCGACGATCCCAT
	Rev CACACCCGTCTTTACTTCCTC
ATG16L1	Fwd TCTGGGACATTCGATCAGAGAG
	Rev CCTTTCTGGGTTTAAGTCCAGG
ATG3	Fwd ACATGGCAATGGGCTACAGG
	Rev CTGTTTGCACCGCTTATAGCA
ATG4B	Fwd GGTGTGGACAGATGATCTTTGC
	Rev CCAACTCCCATTTGCGCTATC
ATG5	Fwd GGTGTCTCTCGCAGATTCATC
	Rev TCAGTCTTCGGCTGAGGTTCT
ATG7	Fwd CAGTTTGCCCCTTTTAGTAGTGC
	Rev CCAGCCGATACTCGTTCAGC
BECN1	Fwd AGAAGCTGTTTCGTCCTGTGG
	Rev AGGTGTTTCCAACATTGGCTC
ULK1	Fwd CCAGAGCAACATGATGGCG
	Rev CCTTCCCGTCGTAGTGCTG
FIP200	Fwd ATCGAAGAGTGTGTGTACCTACAGT
	Rev GCAGGTGGACGATCACATAAGAT
SQSTM1	Fwd GACTACGACTTGTGTAGCGTC
	Rev AGTGTCCGTGTTTCACCTTCC
18S rRNA	Fwd GTAACCCGTTGAACCCCATT
	Rev CCATCCAATCGGTAGTAGCG

Table S6. The primer sequences



(A) Schematic diagram of the construction of the HCC PDX model and subsequent treatments. (B) The effects of betaine treatment on the expression levels of CD133, CD44, SOX2, Nanog, and EpCAM proteins in PDX tumor tissues were analyzed using WB assay. (C-F) HUH-7 and Hep3B cells were subjected to various concentrations of betaine treatment for 24 h, and cell viability was detected. The cell inhibitory rate and IC50 values of HCC cells under betaine treatment were calculated according to the absorbance. (G) HUH-7 and Hep3B cells were subjected to 200 mM of betaine treatment for 24 h, and the effects of betaine on the expression levels of CD133, CD44, SOX2, Nanog, and EpCAM in HCC cells were analyzed using WB assay. *P < 0.05, ** P < 0.01, *** P < 0.001.



(A) The effects of betaine treatment on the expression levels of E-cadherin, N-cadherin, Vimentin, MMP2, Ki-67, and PCNA proteins in PDX tumor tissues were analyzed using WB assay. (B-C) HCC cells were treated with betaine and subjected to sphere cells formation, then sphere cells were dissociated and subjected to colony formation, and transwell migration and invasion assays. (Scale bar = $100 \mu m$). (D) HCC cells were treated with betaine and subjected to sphere cells formation, the expression levels of E-cadherin, N-cadherin, Vimentin, MMP2, Ki-67, and PCNA proteins in HCC sphere cells were detected using WB assay. (E) Time scale diagram of tail vein-lung metastasis assay.



(A) Hep3B cells were treated with betaine, and the expression levels of LC3 I/II proteins were detected using WB assay. (B) After betaine treatment, the expression levels of LC3B protein in PDX

tumor tissues were detected using IHC assay (Scale bar = 100 μ m). (C) Hep3B cells were treated with betaine, and the intracellular autophagosomes were captured using a TEM (scale bar = 2 μ m for left panel, 1 μ m for right panel). A statistical graph is shown. (D) Hep3B cells were pre-transfected with mCherry-GFP-LC3B, and then subjected to betaine treatment. The red and yellow puncta were captured by a confocal microscope and quantitated (scale bar = 20 μ m). A statistical graph is shown. (E) Hep3B cells were treated with betaine, and the expression levels of Nanog and LC3B proteins in the same cells were detected using IF assay (scale bar = 20 μ m). (F) After being exposed to betaine, HCQ, or combined betaine and HCQ treatments, the expression levels of CD133, CD44, SOX2, Nanog, EpCAM, and LC3 I/II proteins in PDX tumors tissues were detected using WB assay. (G-H) After being exposed to betaine, HCQ, or combined betaine, HCQ, or combined betaine and HCQ treatments, the expression levels of CD133, Nanog and LC3B in same area of PDX tumor tissues were detected via IF co-staining assay (scale bars = 50 μ m). *P < 0.05, **P < 0.01, ***P < 0.001.



(A-F) After being transfected with shATG5, siATG5, siBHMT, shATG3, siATG3, and siYTHDF1, the expression levels of ATG5, BHMT, ATG3, and YTHDF1 mRNA in HCC cells were detected using qPCR assay. (G-K) After being transfected with shATG5, siATG5, siBHMT, shATG3, and siATG3, the expression levels of ATG5, BHMT, and ATG3 protein in HCC cells were detected using

WB assay.



(A-B) HCC cells were pre-transfected with shATG5, and then subjected to betain treatment. The intracellular autophagosomes were captured using a TEM (scale bar = $2 \mu m$ for left panel, $1\mu m$ for

right panel). A statistical graph is shown. (C-D) HCC cells were treated with betaine, HCQ, or combined betaine and HCQ. The intracellular autophagosomes were captured via a TEM (scale bar = 2 μ m for left panel, 1 μ m for right panel). A statistical graph is shown. (E-F) HCC cells were pre-transfected with mCherry-GFP-LC3B and siATG5, and then subjected to betaine treatment. The red and yellow puncta were captured by a confocal microscope and quantitated (scale bar = 20 μ m). A statistical graph is shown. (G-H) HCC cells were pre-transfected with mCherry-GFP-LC3B, and then subjected to betaine, HCQ, or combined betaine and HCQ treatments. The red and yellow puncta were captured by a confocal microscope and quantitated (scale bar = 20 μ m). A statistical graph is shown. (G-H) HCC cells were pre-transfected with mCherry-GFP-LC3B, and then subjected to betaine, HCQ, or combined betaine and HCQ treatments. The red and yellow puncta were captured by a confocal microscope and quantitated (scale bar = 20 μ m). A statistical graph is shown. * P < 0.05, ** P < 0.01, *** P < 0.001.



(A) Hep3B cells were pre-transfected with shATG5, and then subjected to betaine treatment. The expression levels of CD133, CD44, SOX2, Nanog, EpCAM, and LC3 I/II proteins were detected using WB assay. (B) Hep3B cells were subjected to betaine, HCQ, or combined betaine and HCQ treatments. The expression levels of CD133, CD44, SOX2, Nanog, EpCAM, and LC3 I/II proteins were detected using WB assay. (C) HCC cells were pre-transfected with shATG5, and then subjected to betaine treatment. The stemness of HCC cells under different treatments was measured using *in vitro* limiting dilution assay. (D) HCC cells were subjected to betaine, HCQ, or combined betaine and HCQ treatments, the stemness of HCC cells under different treatment was measured using *in vitro* limiting dilution assay.





(A) After being exposed to betaine, HCQ, or combined betaine and HCQ treatments, the expression levels of E-cadherin, N-cadherin, Vimentin, MMP2, Ki-67, and PCNA proteins in PDX tumors tissues were detected using WB assay. (B) Hep3B cells were pre-transfected with shATG5 and subjected to betaine treatment for generation of sphere cells. The expression levels of E-cadherin, N-cadherin, Vimentin, MMP2, Ki-67, and PCNA proteins in Hep3B sphere cells were detected using WB assay. (C) Hep3B cells were subjected to betaine, HCQ, or combined betaine and HCQ treatments for generation of sphere cells. The expression levels of E-cadherin, Vimentin, MMP2, Ki-67, and PCNA proteins in levels of E-cadherin, N-cadherin, Vimentin, MMP2, Ki-67, and PCNA proteins in Hep3B sphere cells were detected using WB assay. (D) Hep3B cells were pre-transfected with shATG5, and then subjected to betaine treatment. The tumor sphere formation ability of HUH-7 cells under different treatments was measured (scale bars = 100 µm).

(E) Hep3B cells were subjected to betaine, HCQ, or combined betaine and HCQ treatments, and the tumor sphere formation ability of HUH-7 cells under different treatments was measured (scale bars = 100 μ m). (F-G) Statistical graphs of the tumor sphere formation assays under different treatments. (H-I) HCC cells were pre-transfected with shATG5 and subjected to betaine treatment for generation of sphere cells. After being dissociated and diluted, sphere cells were subjected to colony formation, and transwell migration and invasion assays (scale bars = 100 μ m). (J-K) HCC cells were subjected to betaine, HCQ, or combined betaine and HCQ treatments for generation of sphere cells. After being dissociated and diluted, sphere cells were subjected to betaine, HCQ, or combined betaine and HCQ treatments for generation of sphere cells. After being dissociated and diluted, sphere subjected to colony formation, and transwell migration and invasion assays (scale bars = 100 μ m). (L-M) Statistical graphs of transwell migration and invasion assays of Hep3B sphere cells are shown. *P < 0.05, **P < 0.01, ***P < 0.001.



(A-B) After being exposed to betaine, HCQ, or combined betaine and HCQ, the m⁶A modification in PDX tumor tissues were detected using dot blot and quantified using the EpiQuik m⁶A methylation quantification kit, respectively. (C-D) After treated with betaine, HCQ or combined betaine and HCQ, the m⁶A modification in HCC cells were detected using dot blot and quantified using the EpiQuik m⁶A methylation quantification kit, respectively. (E-F) HCC cells were pretransfected with shATG5, and then were subjected to betaine treatment. The m⁶A modification in HCC cells were detected using dot blot and quantified using the EpiQuik m⁶A methylation quantification kit, respectively. (G-H) After treated with betaine, HCQ or combined betaine and HCQ, the SAM levels in PDX tumor tissues and HCC cells were detected via SAM ELISA kit. (I)

HCC cells were pre-transfected with shATG5, and then subjected to betain treatment. The SAM levels in HCC cells were detected via SAM ELISA kit. ns: not significant; ***P < 0.001.



Figure 9

(A-B) HCC cells were pre-transfected with siBHMT, and then subjected to betaine or combined betaine and SAM treatments. The intracellular autophagosomes were captured using a TEM (scale bar = 2 μ m for left panel, 1 μ m for right panel). A statistical graph is shown. (C-D) HCC cells were pre-transfected with mCherry-GFP-LC3B and siBHMT, and then subjected to betaine or combined betaine and SAM treatments. The red and yellow puncta were captured by a confocal microscope and quantitated (scale bar = 20 μ m). A statistical graph is shown. *P < 0.05, **P < 0.01, ***P < 0.001.



(A-B) HCC cells were pre-transfected with shATG3, and then subjected to betaine treatment. The intracellular autophagosomes were captured using a TEM (scale bar = 2 μ m for left panel, 1 μ m for right panel). A statistical graph is shown. (C-D) HCC cells were pre-transfected with mCherry-GFP-LC3B and siATG3, and then subjected to betaine treatment. The red and yellow puncta were captured by a confocal microscope and quantitated (scale bar = 20 μ m). A statistical graph is shown. *P < 0.05, **P < 0.01, ***P < 0.001.



(A) HCC cells were pre-transfected with shATG3, and then treated with betaine. The tumor sphere formation ability of HCC cells under different treatments was measured (scale bars = $100 \mu m$). (B) HUH-7 cells were pre-transfected with shATG3 and subjected to betaine treatment for generation of sphere cells. Then, HUH-7 sphere cells were diluted in a gradient and injected subcutaneously into nude mice. The number of tumors in each group was counted after 30 days. The tumor formation frequency (n = 5 per group) was shown. (C-D) HCC cells were pre-transfected with shATG3, and then subjected to betaine treatment. The stemness of HCC cells under different treatments was measured using *in vitro* limiting dilution assay. (E) Hep3B cells were pre-transfected with shATG3, and EpCAM proteins were detected using WB assay. (F-H) HCC cells were pre-transfected with shATG3 and subjected to betaine treatment for generation of sphere cells. After being dissociated and diluted, HCC sphere cells were subjected to colony formation, and transwell migration and invasion assays (scale bar = $100 \mu m$). A statistical graph of transwell migration and invasion assays

of Hep3B sphere cells is shown. (I) HCC cells were pre-transfected with shATG3 and subjected to betaine treatment for generation of sphere cells. The expression levels of E-cadherin, N-cadherin, Vimentin, MMP2, Ki-67, and PCNA proteins in Hep3B sphere cells were detected using WB assay. *P < 0.05, **P < 0.01, ***P < 0.001.